Previous Article | Next Article ![]()
Infection and Immunity, August 2003, p. 4368-4374, Vol. 71, No. 8
0019-9567/03/$08.00+0 DOI: 10.1128/IAI.71.8.4368-4374.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.
Department of Veterinary Science and Microbiology, The University of Arizona, Tucson, Arizona 85721
Received 11 April 2003/ Returned for modification 16 May 2003/ Accepted 27 May 2003
|
|
|---|
|
|
|---|
Host cell adhesion is the critical first step in bacterial colonization, subsequently leading to infection, in the case of pathogens. Adhesion results from the interaction of a number of surface-exposed or secreted bacterial proteins with host cells and molecules. One such class of adhesins is cell surface-expressed proteins that can bind to components of the host extracellular matrix (ECM). In gram-positive genera, many of these proteins belong to the MSCRAMM (microbial surface components recognizing adhesive matrix molecules) family, a class of cell surface-anchored proteins that bind to one or more components of the host ECM, such as fibronectin, laminin, or collagen (26). MSCRAMMs have in common a conserved architecture, consisting of an N-terminal signal sequence required for secretion, a ligand-binding domain, one or more sets of polypeptide repeats, and a C-terminal region involved in cell wall anchoring (26). It is hypothesized that the ECM component forms a molecular bridge between the bacterial MSCRAMMs and host cell integrins (10, 32), resulting in bacterial adhesion to the host.
Furthermore, these molecules act as virulence factors, as adhesion mediated by fibronectin-binding MSCRAMMs promotes invasion of host cells (reviewed in reference 10). The collagen adhesin of Staphylococcus aureus, Cna, is a virulence factor in several experimental animal models, including murine osteomyelitis (6) and rabbit keratitis (31). Similarly, Ace, the collagen adhesin of Enterococcus faecalis, is important for adherence to dentin in tooth root canals (9).
This report describes the identification of the first A. pyogenes ECM-binding MSCRAMM, CbpA, which is capable of binding collagen types I, II, and IV. CbpA mediates adhesion of A. pyogenes to collagen-expressing cell lines, and this adhesion can be inhibited, in a dose-dependent manner, by the presence of exogenous CbpA.
|
|
|---|
MCR strains (Gibco-BRL) were grown on Luria-Bertani (Difco) agar or in Luria-Bertani broth at 37°C. Antibiotics were added as follows: for A. pyogenes strains, erythromycin at 15 µg/ml and kanamycin at 30 µg/ml; for E. coli strains, ampicillin at 100 µg/ml, chloramphenicol at 30 µg/ml, erythromycin at 200 µg/ml, and kanamycin at 50 µg/ml.
DNA techniques.
E. coli plasmid DNA extraction, transformation, DNA restriction, ligation, agarose gel electrophoresis, and Southern transfer of DNA to nylon membranes were performed essentially as previously described (2). Electroporation-mediated transformation of A. pyogenes strains was performed as previously described (11). A. pyogenes genomic DNA was isolated by the method of Pospiech and Neumann (29). A library of A. pyogenes BBR1 genomic DNA was constructed in
GEM-12 in accordance with the manufacturer's (Promega) instructions. The methods used for bacteriophage growth and DNA purification were essentially as previously described (2). Preparation of DNA probes with oligonucleotide primers internal to specific genes, DNA hybridization, and probe detection were performed with the DIG DNA Labeling and Detection Kit (Roche) as recommended by the manufacturer. PCR DNA amplification was performed with Taq DNA polymerase (Promega) and the supplied reaction buffer for 35 cycles consisting of 1 min at 94°C, 1 min at 55°C, and 1 min/kb at 72°C, with a final extension step of 72°C for 5 min.
Nucleotide sequence determination.
The sequence of cbpA was determined from overlapping subclones of
JGS27 by automated DNA sequencing. Sequencing was performed on both strands, crossing all restriction sites, with KS, SK, T7, M13 universal, or M13 reverse sequencing primers or oligonucleotide primers designed to the sequence of the cbpA gene region. Sequencing reactions were performed by the University of Arizona Genomic Analysis and Technology Core with a 377 DNA sequencer (Applied Biosystems Inc.).
Computer sequence analysis. Nucleotide sequence data were compiled with the Sequencher program (GeneCodes). Database searches were performed with the BlastX and BlastP algorithms (1). Sequence analysis was performed with the suite of programs available through the Genetics Computer Group, Inc. (University of Wisconsin). Signal sequence prediction was performed with SignalP (23). Transcriptional terminators were identified with mfold (36). Multiple-sequence alignments were performed with CLUSTAL W (40).
Cloning and purification of recombinant, six-His tagged CbpA (HIS-CbpA). A portion of the cbpA gene, lacking the coding region for the signal sequence, was amplified from A. pyogenes BBR1 genomic DNA by PCR with 5' primer 5'-CGCCGCGCACGCTAGCGGCAAAGATT-3', containing an in-frame mutation encoding an NheI site (underlined), and 3' primer 5'-TACGATACGGTCTTTCTTCTGG-3'. These primers amplified an 884-bp product stretching from base 83 to base 966 of the cbpA gene. The PCR fragment was digested with NheI-BglII and cloned into NheI-BglII-digested pTrcHisB (Invitrogen) to generate pJGS583. A 3.5-kb BglII-EcoRV fragment, containing the 3' end of cbpA, was cloned into pJGS583 digested with BglII and PstI (blunted with T4 DNA polymerase) to generate pJGS591. pJGS591 encodes HIS-CbpA, a 1,137-amino-acid (aa) protein comprising 1,123 aa of the mature CbpA protein with an N-terminal extension of 14 aa encoded by pTrcHisB, including a six-His sequence.
Cultures for preparation of HIS-CbpA were grown to an optical density at 600 nm of 0.6 prior to induction with 2.5 mM isopropyl-ß-D-thiogalactopyranoside (IPTG) for 3 h. Cells were harvested by centrifugation at 5,000 x g, and the cell pellet was resuspended in 20 mM Tris-HCl-100 mM NaCl, pH 8.0. The cells were disrupted by two passages through a French pressure cell (Aminco) at 138 MPa, and the insoluble material was removed by centrifugation at 12,000 x g. HIS-CbpA was purified from the soluble fraction with TALON metal affinity resin (Clontech), in accordance with the manufacturer's instructions. HIS-CbpA was eluted from the resin with 50 mM imidazole-20 mM Tris-HCl-100 mM NaCl, pH 8.0. Total protein concentration was determined with Bradford protein assay reagent (Bio-Rad).
The HIS-CbpA used in adhesion assays was dialyzed against 400 volumes of Iscove's modified Dulbecco's medium (IMDM; Life Technologies) supplemented with 10% fetal bovine serum (FBS; Omega Scientific, Inc.) for 18 h at 4°C.
Preparation of goat antiserum to HIS-CbpA. A female goat was immunized with 500 µg of HIS-CbpA in Ribi Adjuvant System (Corexa) intramuscularly in the hind leg at two sites. A similar booster immunization of 500 µg of HIS-CbpA in Ribi Adjuvant System was administered on days 14 and 28. Blood was collected on day 54, and serum was harvested from the clotted blood by centrifugation at 400 x g. Preimmune serum was prepared in a similar manner prior to immunization.
Sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) and Western blotting techniques. Prior to electrophoresis, whole A. pyogenes cells were treated with mutanolysin and lysozyme (Sigma) essentially as previously described (42). Enzyme-treated whole A. pyogenes cells, whole E. coli cells, or HIS-CbpA was mixed 1:1 with sample buffer (0.2 M Tris-HCl [pH 6.8], 2.5% SDS, 10% ß-mercaptoethanol, 20% glycerol, 0.013% bromophenol blue) and heated in a boiling water bath for 10 min prior to electrophoresis in an SDS-10% (wt/vol) polyacrylamide gel (2). The separated proteins were stained with Coomassie brilliant blue or transferred to nitrocellulose essentially as previously described (2). Western blots were immunostained with 1/100 goat anti-HIS-CbpA and 1/500 rabbit anti-goat immunoglobulin G (IgG; heavy and light chains)-peroxidase conjugate (KPL) as the primary and secondary antibodies, respectively.
Far Western blotting was performed the same way as Western blotting, with the following exceptions. Membranes were blocked by incubation with 5% bovine serum albumin (BSA) in 0.01 M phosphate-buffered saline (PBS), pH 7.2, for 30 min at room temperature with shaking and subsequent incubation with 50 µg of bovine collagen type I (Sigma) per ml in PBS for 2 h as described above and immunostained with 1/100 rabbit anti-bovine collagen I (Chemicon) and 1/500 goat anti-rabbit IgG (heavy and light chains)-peroxidase conjugate (KPL) as the primary and secondary antibodies, respectively.
In order to assess the ECM-binding specificity of CbpA, 5 µg each of bovine collagen type I, bovine collagen type II (Sigma), murine collagen type IV (BD Biosciences), bovine fibronectin (Sigma), and BSA and trypsin inhibitor (irrelevant control proteins) was spotted onto nitrocellulose membranes in a 5-µl volume and allowed to air dry for 10 min. Membranes were incubated with 50 µg of HIS-CbpA per ml for 2 h at room temperature with shaking and immunostained with 1/100 goat anti-HIS-CbpA and 1/500 rabbit anti-goat IgG (heavy and light chains)-peroxidase conjugate (KPL), respectively.
Construction of a cbpA mutant and a complementing plasmid. Construction of a cbpA mutant was done with an allelic-exchange plasmid in which the coding region for the collagen-binding domain was completely replaced with an erm(X) cassette. A 4.9-kb EcoRV fragment containing the entire cbpA gene was cloned into pHSS19 (22) to generate pJGS524. The 0.7-kb BglII-NruI fragment that encodes the CbpA collagen-binding domain was replaced with a 1.6-kb erm(X) cassette (38), resulting in recombinant plasmid pJGS531. pJGS531, based on a ColE1 replicon, acted as a suicide vector in A. pyogenes (13). pJGS531 plasmid DNA was introduced into A. pyogenes BBR1 cells by electroporation, and recombinants were selected on BHI-blood agar containing erythromycin. The 4.9-kb EcoRV fragment containing the entire cbpA gene was cloned into the PvuII site in pEP2 (30) to construct the complementing plasmid, pJGS557.
Tissue culture cell adhesion assays. HeLa (human epithelial) cells and 3T6 cells, a collagen-secreting murine fibroblast cell line (7), were cultured in IMDM-10% FBS with 100 µg of gentamicin (Sigma) per ml in a humidified 5% CO2 atmosphere at 37°C. For adhesion assays, cells in IMDM-10% FBS, without gentamicin, were seeded into 24-well plates at 4 x 105 cells per well in 1-ml volumes. The cells were incubated at 37°C in 5% CO2 for 18 h prior to the addition of stationary-phase A. pyogenes bacteria. Bacterial adhesion was assessed after 2 h of incubation at 37°C in 5% CO2. Cell monolayers were washed three times with PBS to remove nonadherent bacteria. Adherent bacteria were recovered by treatment of the cell monolayers with 1 ml of 0.1% Triton X-100 for 10 min on ice, and viable bacteria were enumerated by dilution plating.
Assays to determine whether HIS-CbpA can competitively inhibit adhesion of wild-type A. pyogenes were performed as described above, except that HIS-CbpA in IMDM-10% FBS was added to the cell monolayers at 0 to 50 µg/ml (final concentration) and they were incubated for 1 h prior to the addition of A. pyogenes BBR1 bacteria, also resuspended in the appropriate concentration of HIS-CbpA in IMDM-10% FBS. All adhesion assays were performed in triplicate on at least two separate occasions.
Detection of collagen expression by tissue culture cells. HeLa and 3T6 cells were grown to a confluent monolayer in chamber slides (Lab-Tek), fixed in 10% buffered formalin, and stained by the Picrosirus Red method (16).
Statistical analysis. A one-way analysis of variance was performed on the data from the tissue culture adhesion assays with Excel statistical software (Microsoft, Inc.).
Nucleotide sequence accession number. The cbpA sequence data obtained in this study were submitted to the DDBJ/EMBL/GenBank databases and assigned accession number AY223543.
|
|
|---|
![]() View larger version (41K): [in a new window] |
FIG. 1. A. pyogenes BBR1 binds collagen type I. Whole A. pyogenes BBR1 cells were subjected to SDS-10% (wt/vol) PAGE. Separated proteins were transferred to nitrocellulose, and Far Western blotting was performed either in the absence (-Cn) or in the presence (+Cn) of collagen type I. The positions of molecular size standards (sizes are in kilodaltons) are shown on the left. The arrow indicates the position of an approximately 120-kDa A. pyogenes protein that is able to bind collagen I.
|
GEM-12 library of A. pyogenes BBR1 genomic DNA. One hybridizing plaque,
JGS27, contained a 13.9-kb partial Sau3AI insert, and from this, a series of BamHI, EcoRI, EcoRV, and NotI subclones were constructed in pBCKS (Stratagene). The DNA sequence of the cbpA gene region was deduced from these overlapping clones, and the 3,456-bp cbpA gene was identified (Fig. 2). This gene encodes a protein with a predicted molecular mass of 124.7 kDa, consistent with that identified by Far Western blotting (Fig. 1). No E. coli
70-like promoter sequences were apparent upstream of cbpA, and 14 bp downstream of the stop codon was a putative rho-independent terminator (
G = -18.4 kcal/mol). Immediately upstream of cbpA, and transcribed in the opposite direction, was an open reading frame, orf302 (Fig. 2), encoding a protein with amino acid similarity to a Streptomyces coelicolor putative transcriptional regulatory protein (GenBank accession no. NP_625638; 23.2% identity, 45.9% similarity). Orf302 possesses a C-terminal helix-turn-helix motif, suggesting that orf302 encodes a DNA-binding protein. Upstream of orf302 was orf309' (Fig. 2), a partially sequenced open reading frame, the translated product of which has amino acid similarity to the high-affinity choline transport proteins, with the most similarity to that of Erwinia amylovora (GenBank accession no. AF264948; 34.1% identity and 54.2% similarity over the available region of Orf309'). The translation of orf309' contains three predicted transmembrane domains, suggesting membrane localization, consistent with the possibility that Orf309' is a transporter. The orientation of orf302, transcribed in the opposite direction to cbpA (Fig. 2), and the presence of a strong transcriptional terminator suggest that cbpA is monocistronic. |
View larger version (7K): [in a new window] |
FIG. 2. Map of the A. pyogenes BBR1 cbpA gene region. The BglII (B), EcoRI (E), EcoRV (V), and NruI (N) sites used to clone portions of the cbpA gene are shown.
|
![]() View larger version (40K): [in a new window] |
FIG. 3. Deduced amino acid sequence of CbpA. The predicted signal peptide cleavage site is denoted by the vertical arrow. The putative collagen-binding subdomain is underlined. The B domains, B1, B2, B3, and B4, are double underlined, with the start of each repeat indicated by bent arrows. The LPXTG-like motif and the charged C terminus are boxed in black, and the intervening membrane-spanning domain is boxed. Amino acid numbers are on the right.
|
![]() View larger version (28K): [in a new window] |
FIG. 4. Alignment of the amino acid sequences of the putative collagen-binding subdomains of A. pyogenes CbpA, S. aureus Cna (GenBank accession no. M81736), E. faecalis Ace (GenBank accession no. AF260872), and E. faecium Acm (GenBank accession no. AY135217). Where three or more amino acids are identical, they are boxed in black. The five amino acids thought to be critical for collagen binding of Cna (39) are indicated by arrows. Amino acid numbers for each protein are on the right.
|
At the C terminus of CbpA was a sequence similar to the cell wall sorting signals found in surface-expressed proteins of gram-positive bacteria (37). Like all of the other A. pyogenes cell surface-expressed proteins sequenced to date, CbpA contained a variant LPxTG motif (Fig. 3). The prediction that CbpA is a cell surface-expressed protein is consistent with its identification in the A. pyogenes cell wall (data not shown) and its function as an adhesin.
Determination of the prevalence of the cbpA gene by DNA dot blotting. Genomic DNA was prepared from 75 A. pyogenes strains and subjected to hybridization at high stringency with a probe spanning bases 254 to 965 of cbpA, which included the putative collagen-binding domain. The DNA from 36 A. pyogenes isolates hybridized to the probe (data not shown), indicating that cbpA is found in 48.0% of the A. pyogenes isolates tested. Twenty-two (48.9%) of 45 bovine A. pyogenes isolates carried cbpA, while 12 (40%) of 20 porcine A. pyogenes isolates were positive for the gene. In contrast, six (100%) of six avian isolates, including five from cases of turkey osteomyelitis, carried cbpA. The four remaining isolates, two canine, one feline, and one of unknown origin, did not carry cbpA.
Cloning and expression of HIS-CbpA.
In order to prepare recombinant CbpA for the production of antibodies and ECM-binding specificity studies, cbpA lacking the coding sequence for the signal peptide was cloned into the six-His tag vector pTrcHisB to generate pJGS591 as described in Materials and Methods. SDS-PAGE and Coomassie brilliant blue staining of IPTG-induced cultures of DH5
MCR(pJGS591) identified the presence of an approximately 123-kDa band, which corresponded to the predicted size of HIS-CbpA (Fig. 5A). Purified HIS-CbpA retained collagen-binding activity, as determined by Far Western blotting (Fig. 5B).
![]() View larger version (43K): [in a new window] |
FIG. 5. Overexpression and purification of HIS-CbpA. Whole-cell lysates of IPTG-induced cultures of DH5 MCR(pTrcHisB) (lane 1), DH5 MCR(pJGS591) (lane 2), and 150 ng of purified HIS-CbpA (lane 3) were subjected to SDS-PAGE and Coomassie brilliant blue staining (A). One hundred fifty nanograms of purified HIS-CbpA (lane 4) was subjected to Far Western blotting with collagen type I as the ligand (B). One hundred fifty nanograms of purified HIS-CbpA (lane 5), whole A. pyogenes BBR1 cells (lane 6), or whole CbpA-1 cells (lane 7) was subjected to Western blotting with anti-HIS-CbpA diluted 1/100 (C). The positions of molecular size standards (sizes are in kilodaltons) are shown on the left. The arrow indicates the position of CbpA or HIS-CbpA.
|
The presence of CbpA in whole-cell samples of A. pyogenes BBR1 harvested at 10 time points throughout the cell cycle was determined. CbpA was detected in approximately equivalent amounts at all time points (data not shown). While this result does not indicate whether expression of cbpA is constitutive, it indicates that, like Cna (17), CbpA is always present on the A. pyogenes cell surface.
ECM-binding specificity of HIS-CbpA. The ECM-binding specificity of CbpA was determined by Far Western dot blotting. ECM proteins, collagen types I, II, and IV and fibronectin, were spotted onto nitrocellulose, and the binding of HIS-CbpA was determined (Fig. 6). HIS-CbpA bound all of the collagen types tested but did not bind fibronectin. HIS-CbpA was also unable to bind the irrelevant control proteins BSA and trypsin inhibitor (Fig. 6), indicating the specificity of HIS-CbpA for collagen. Like Cna (39), CbpA appears to recognize the triple-helical structure of collagen, as HIS-CbpA was unable to bind to denatured collagen molecules (data not shown).
![]() View larger version (5K): [in a new window] |
FIG. 6. HIS-CbpA binds collagen types I, II, and IV but not fibronectin. Five micrograms of each protein was spotted onto nitrocellulose and incubated with 50 µg of HIS-CbpA per ml. The binding of HIS-CbpA was detected by immunostaining with anti-HIS-CbpA diluted 1/500. 1, BSA; 2, trypsin inhibitor; 3, bovine collagen type I; 4, bovine collagen type II; 5, murine collagen type IV, 6: bovine fibronectin. Immunostaining with preimmune serum diluted 1/500 resulted in no reactivity (data not shown).
|
Adhesion of A. pyogenes to epithelial and fibroblast cell lines. In order to confirm that 3T6 and HeLa cells expressed collagen under the culture conditions used, Picrosirus Red staining was performed. Both cell lines expressed collagen, with 3T6 cells expressing more collagen than HeLa cells (data not shown). Wild-type A. pyogenes strain BBR1 adhered similarly to HeLa and 3T6 cells, with average adhesions of 2.6 and 3.2%, respectively (Fig. 7A). The CbpA-1 mutant had an impaired ability to bind to HeLa and 3T6 cells, with an average adhesion of 1.5% for both cell lines (Fig. 7A). The differences in adhesion between the wild-type and cbpA mutant strains were significant, with P < 0.001 in both cases. Complementation of the CbpA-1 mutant with pJGS557 was able to reverse the adhesion defect (average adhesions of 7.7 and 7.5% for HeLa and 3T6 cells, respectively; Fig. 7A). The substantially increased adhesion of the complemented mutant over that of the wild type is possibly due to a gene dosage effect, as the complementing plasmid carrying cbpA is multicopy. Introduction of pEP2 into CbpA-1 had no effect on adhesion (Fig. 7A). These findings suggest that CbpA mediates binding of A. pyogenes to collagen-expressing cell lines, since its absence results in significantly reduced adhesion and the binding defect can be complemented in trans.
![]() View larger version (43K): [in a new window] |
FIG. 7. CbpA mediates adhesion of A. pyogenes strains to HeLa or 3T6 cells. (A) A. pyogenes strains were added to monolayers of HeLa (gray bars) or 3T6 (open bars) cells and allowed to adhere for 2 h at 37°C prior to washing and recovery of cell-associated bacteria. (B) HIS-CbpA, at the concentrations indicated, was preincubated with HeLa (gray bars) or 3T6 (open bars) cell monolayers for 1 h prior to addition of A. pyogenes BBR1. Adhesion is expressed as a percentage of the number of bacteria originally added to the cells. Error bars indicate one standard deviation of the mean calculated from the averages of two independent experiments performed in triplicate.
|
In order to determine whether exogenous CbpA could block the adhesion of wild-type BBR1, 0.5 to 50 µg of HIS-CbpA per ml was added 1 h prior to, and simultaneously with, the addition of A. pyogenes BBR1. A dose-dependant response was observed, with 50 µg of HIS-CbpA per ml significantly reducing the ability of BBR1 to adhere to HeLa or 3T6 cells (P < 0.001 in both cases; Fig. 7B).
|
|
|---|
CbpA was most similar to Cna of S. aureus (28) and, like that protein, also contained the domain structure typical of MSCRAMM proteins, including a signal peptide, a collagen-binding domain, repetitive B domains, and a cell wall anchoring domain. Recombinant HIS-CbpA bound collagen types I, II, and IV but not fibronectin and appears to recognize the triple-helical structure of collagen, as it was unable to bind to denatured collagens.
Collagen binding has been ascribed to a subdomain of the nonrepetitive A domain of Cna, Ace, and Acm (20, 34, 39). Within this subdomain, these three proteins have in common the conservation of five amino acids that have been shown to be important for collagen binding in Cna (27, 39) (Fig. 4). CbpA contained substitutions for two of these amino acids, glycine for tyrosine at position 179 and arginine for asparagine at position 198 (residues 175 and 193 in Cna, respectively). The replacement of asparagine 198 with arginine is of interest, as mutational analysis of Cna indicated that replacement of asparagine 193 with lysine, another positively charged amino acid, substantially reduced the affinity of the mutant protein for collagen (39). It is possible that CbpA has a reduced affinity for collagen compared with Cna or that other substitutions in this subdomain or the entire A domain result in compensatory structural changes allowing collagen binding. The latter hypothesis is supported by the finding that, while the Ace and Cna subdomains bind collagen, the entire A domains do so with greater affinity, indicating that regions flanking the subdomain probably contribute to the formation of an optimal collagen-binding structure (32, 34).
Variability in the number of B domains has been reported for Cna (24), Ace (19), and Acm (20). Although the B domains from the different collagen-binding proteins are not similar, within a protein species they are highly conserved with respect to both length and sequence. In contrast, the B domains of CbpA are variable in length (90 to 96 aa) and have significant sequence divergence (30.2 to 95.7% identity; Fig. 3). The role of the B domains has not been established, although it is known that a recombinant Cna A domain binds collagen in the absence of any B domains (33). Similarly, a truncated form of HIS-CbpA, containing only the A subdomain (aa 29 to 391), bound all of the collagen types at wild-type levels (data not shown).
CbpA mediates adhesion to host cells, as the cbpA mutant, CbpA-1, exhibits reduced adhesion to both HeLa and 3T6 cells. This defect could be complemented in trans by provision of cbpA on a replicating plasmid. Introduction of cbpA into a strain naturally lacking this gene resulted in increased adhesion to HeLa and 3T6 cells, further supporting the hypothesis that CbpA is a host cell adhesin. The mechanism of MSCRAMM binding to host cells is still somewhat unclear. However, structural analyses of Cna and human
1ß1 integrin revealed that both proteins contain collagen-binding "trenches," which could allow collagen to act as a molecular bridge between the bacterial MSCRAMM and the host cell integrin (32). Similar analyses of the Ace A subdomain revealed that it also formed a trench-like structure (34). The finding that exogenous HIS-CbpA blocks adherence of A. pyogenes to host cells in a dose-dependent manner is consistent with this mechanism of action.
Collagen adhesins are thought to act as disease-specific virulence factors, specifically by promoting adhesion to collagen-rich tissues. Introduction of cna into a cna-defective S. aureus strain resulted in an increased ability to adhere to cartilage and cause septic arthritis in mice (25). Furthermore, an S. aureus cna mutant had a significantly reduced ability to cause murine hematogenous osteomyelitis (6). Similarly, Ace mediates adhesion of E. faecalis to dentin in root canals, as an ace mutant had a significantly reduced ability to do so (9).
The presence and/or expression of genes encoding collagen adhesins is not ubiquitous within a bacterial species. The ace gene is carried by all of the E. faecalis isolates tested (n = 165), although these strains were not tested for the ability to bind collagen (5). acm was carried by all of the strains tested (n = 32), but only 34.4% of the isolates expressed the ability to bind collagen, as a result of deletions, mutations, or the presence of insertion sequences in the gene or its promoter region (20). In contrast, only approximately 50% of S. aureus strains carry cna, although this usually correlates with the ability of the isolate to bind collagen (35).
Similarly, the A. pyogenes cbpA gene is present in only 48.0% of isolates, although these isolates were not tested for the ability to bind collagen. CbpA is the second A. pyogenes protein involved in adhesion that is only encoded by a subset of isolates, as the NanP neuraminidase is present in only 64.2% of strains (15). This result highlights the possibility that A. pyogenes isolates involved in different diseases may be differentially equipped with adhesins. Most of the A. pyogenes isolates used in this study were obtained from soft-tissue infections or as normal flora, and generally, little difference was observed in cbpA carriage in isolates from various animal hosts or diseases. The one exception was turkey osteomyelitis isolates, all of which carried cbpA. Although the number of these isolates is small (n = 5), this result suggests that, like Cna (6), CbpA may act as a virulence factor for A. pyogenes osteomyelitis. While it is unlikely that collagen adhesins target bacteria to tissue-specific sites, such as bone or cartilage, its presence on the bacterial cell may promote the colonization of these collagen-rich tissues, enhancing the ability of isolates expressing a collagen-binding protein to initiate infection.
GEM-12 library and Hien Trinh and Dawn Bueschel for excellent technical assistance. Partial support for this work was provided by U.S. Department of Agriculture Hatch ARZT-136724-H-02-123.
|
|
|---|
1ß1 integrin and Staphylococcus aureus Cna MSCRAMM. J. Biol. Chem. 274:24906-24913.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»